Shire Adderall XR (correction)
Executive Summary
Shire's Adderall XR is third once-daily attention deficit hyperactivity disorder agent on the market, following Alza's Concerta and Celltech's Metadate CD (1"The Pink Sheet" Oct. 15, p. 7). Shire is conducting the Adderall XR open-label study in children, not Novartis